Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily

In a randomized, phase III trial of nilotinib versus imatinib in patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia in chronic phase, more patients had suboptimal response or treatment failure on front-line imatinib than on nilotinib. Patients with suboptimal res...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Hughes, Timothy P., Hochhaus, Andreas, Kantarjian, Hagop M., Cervantes, Francisco, Guilhot, François, Niederwieser, Dietger, le Coutre, Philipp D., Rosti, Gianantonio, Ossenkoppele, Gert, Lobo, Clarisse, Shibayama, Hirohiko, Fan, Xiaolin, Menssen, Hans D., Kemp, Charisse, Larson, Richard A., Saglio, Giuseppe
Natura: Artigo
Lingua:Inglês
Pubblicazione: Ferrata Storti Foundation 2014
Soggetti:
Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4077082/
https://ncbi.nlm.nih.gov/pubmed/24532039
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2013.091272
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi